Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 258 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People October 18, 2023 What to Expect During Recovery From a Bone Marrow Transplant: An... June 20, 2023 Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly... June 30, 2026 Load more HOT NEWS Can we grow the treatments of tomorrow? – That Cancer Conversation SABCS 2021: New Research and Updates in Breast Cancer Treatment and... Determining Fluid Requirements Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated...
